USML vs. CURE
USML (ETRACS 2x Leveraged MSCI US Minimum Volatility Factor TR ETN) and CURE (Direxion Daily Healthcare Bull 3x Shares) are both Leveraged Equities funds - USML tracks the MSCI USA Minimum Volatility Index while CURE tracks the Health Care Select Sector Index (300%). Both are passively managed. Over the past 5 years, USML returned 7.54%/yr vs 1.51%/yr for CURE. A 0.78 correlation means they provide meaningful diversification when combined. USML charges 0.95%/yr vs 1.08%/yr for CURE.
Performance
USML vs. CURE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, USML achieves a 1.74% return, which is significantly higher than CURE's -7.96% return.
USML
- 1D
- 0.67%
- 1M
- 2.24%
- YTD
- 1.74%
- 6M
- 1.57%
- 1Y
- 3.61%
- 3Y*
- 15.23%
- 5Y*
- 7.54%
- 10Y*
- —
CURE
- 1D
- -0.55%
- 1M
- 17.48%
- YTD
- -7.96%
- 6M
- -6.00%
- 1Y
- 28.51%
- 3Y*
- 3.05%
- 5Y*
- 1.51%
- 10Y*
- 13.49%
USML vs. CURE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
USML ETRACS 2x Leveraged MSCI US Minimum Volatility Factor TR ETN | 1.74% | 9.33% | 23.97% | 11.37% | -22.87% | 42.12% |
CURE Direxion Daily Healthcare Bull 3x Shares | -7.96% | 22.55% | -8.47% | -9.40% | -20.51% | 80.16% |
Correlation
The correlation between USML and CURE is 0.55, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.55 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.69 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.78 |
Correlation (All Time) Calculated using the full available price history since Feb 5, 2021 | 0.78 |
Over the past year, the correlation between USML and CURE has dropped to 0.55 - well below their long-term average of 0.78, suggesting their price drivers have been diverging.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
USML vs. CURE — Risk / Return Rank
USML
CURE
USML vs. CURE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ETRACS 2x Leveraged MSCI US Minimum Volatility Factor TR ETN (USML) and Direxion Daily Healthcare Bull 3x Shares (CURE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| USML | CURE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.48 | ||
| Sortino ratioReturn per unit of downside risk | -0.90 | ||
| Omega ratioGain probability vs. loss probability | 1.03 | 1.13 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 0.15 | 0.85 | -0.70 |
| Martin ratioReturn relative to average drawdown | 0.46 | 1.94 | -1.48 |
Loading charts...
Drawdowns
USML vs. CURE - Drawdown Comparison
The maximum USML drawdown since its inception was -35.34%, smaller than the maximum CURE drawdown of -69.19%. Use the drawdown chart below to compare losses from any high point for USML and CURE.
Loading charts...
Drawdown Indicators
| USML | CURE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -35.34% | -69.19% | +33.85% |
Max Drawdown (1Y)Largest decline over 1 year | -13.09% | -31.10% | +18.01% |
Max Drawdown (3Y)Largest decline over 3 years | -19.14% | -51.93% | +32.79% |
Max Drawdown (5Y)Largest decline over 5 years | -35.34% | -52.23% | +16.89% |
Max Drawdown (10Y)Largest decline over 10 years | — | -69.19% | — |
Current DrawdownCurrent decline from peak | -4.83% | -26.94% | +22.11% |
Average DrawdownAverage peak-to-trough decline | -10.38% | -18.16% | +7.78% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.41% | 13.71% | -9.30% |
Volatility
USML vs. CURE - Volatility Comparison
The current volatility for ETRACS 2x Leveraged MSCI US Minimum Volatility Factor TR ETN (USML) is 4.74%, while Direxion Daily Healthcare Bull 3x Shares (CURE) has a volatility of 14.30%. This indicates that USML experiences smaller price fluctuations and is considered to be less risky than CURE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| USML | CURE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 4.74% | 14.30% | -9.56% |
Volatility (6M)Calculated over the trailing 6-month period | 11.57% | 30.87% | -19.30% |
Volatility (1Y)Calculated over the trailing 1-year period | 16.41% | 44.32% | -27.91% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.47% | 43.84% | -19.37% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 24.24% | 49.59% | -25.35% |
USML vs. CURE - Expense Ratio Comparison
USML has a 0.95% expense ratio, which is lower than CURE's 1.08% expense ratio.
Dividends
USML vs. CURE - Dividend Comparison
USML has not paid dividends to shareholders, while CURE's dividend yield for the trailing twelve months is around 1.16%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
CURE Direxion Daily Healthcare Bull 3x Shares | 1.16% | 1.12% | 1.17% | 2.02% | 0.38% | 0.02% | 0.17% | 0.40% | 0.70% | 0.18% |
USML ETRACS 2x Leveraged MSCI US Minimum Volatility Factor TR ETN | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
USML and CURE have a correlation of 0.55, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CURE has higher volatility (14.30%) compared to USML (4.74%). In terms of maximum drawdown, USML dropped -35.34% vs CURE's -69.19%.
On 5-year performance, USML leads with 7.54% vs 1.51% for CURE. On fees, USML is cheaper at 0.95% per year. On volatility, USML has been the lower-risk option at 4.74%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, USML has performed better with a 7.54% return vs 1.51%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
USML is cheaper with a 0.95% expense ratio, compared with 1.08% for CURE.
CURE has the higher dividend yield at 1.16%, compared with 0.00% for USML.
USML tracks MSCI USA Minimum Volatility Index, while CURE tracks Health Care Select Sector Index (300%). They also come from different issuers: UBS and Direxion. Their fees differ too: 0.95% for USML and 1.08% for CURE.
CURE currently has the higher Sharpe Ratio (0.60 vs 0.12), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for USML and CURE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer